Organon (OGN) Asset Utilization Ratio (2021 - 2026)
Organon (OGN) posted quarterly Asset Utilization Ratio of 0.48 for Q1 2026, down 0.59% year-over-year from 0.48 in Q1 2025, and up 1.28% on a QoQ basis from 0.47 in Q4 2025.
Organon (OGN) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Organon (OGN) has reported Asset Utilization Ratio for 6 consecutive years, with 0.48 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 0.59% year-over-year to 0.48; the TTM figure through Mar 2026 stood at 0.48 (down 0.59% YoY), while the FY2025 annual figure was 0.48, down 5.94% from the prior year.
- Asset Utilization Ratio came in at 0.48 for Q1 2026 at Organon, up from 0.47 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.6 in Q2 2022, with the low at 0.47 in Q3 2025.
- Average Asset Utilization Ratio over 5 years is 0.53, with a median of 0.53 recorded in 2024.
- Across the five-year window, Asset Utilization Ratio gained 5.29% in 2022 and retreated 10.72% in 2025, its largest moves.
- Year by year, Asset Utilization Ratio stood at 0.58 in 2022, then decreased by 5.94% to 0.54 in 2023, then dropped by 8.77% to 0.5 in 2024, then dropped by 5.0% to 0.47 in 2025, then rose by 1.28% to 0.48 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.48, 0.47, and 0.47 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 0.63 |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 0.48 |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 0.46 |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 0.50 |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 0.50 |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 0.41 |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 0.52 |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 0.12 |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 0.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.48 |
| Dec 31, 2025 | 0.47 |
| Sep 30, 2025 | 0.47 |
| Jun 30, 2025 | 0.47 |
| Mar 31, 2025 | 0.48 |
| Dec 31, 2024 | 0.50 |
| Sep 30, 2024 | 0.51 |
| Jun 30, 2024 | 0.53 |
| Mar 31, 2024 | 0.53 |
| Dec 31, 2023 | 0.54 |
| Sep 30, 2023 | 0.56 |
| Jun 30, 2023 | 0.57 |
| Mar 31, 2023 | 0.57 |
| Dec 31, 2022 | 0.58 |
| Sep 30, 2022 | 0.60 |
| Jun 30, 2022 | 0.60 |
| Mar 31, 2022 | 0.60 |
| Dec 31, 2021 | 0.57 |
| Sep 30, 2021 | 0.57 |
| Jun 30, 2021 | 0.62 |